Search research articles
Contact Us
Filters
Showing results (11-20 of 71) with videos related to
Page
of 8
Sort By:
Pharmacology & Therapeutics
|
May 5, 2023
The antidepressant actions of ketamine and its enantiomers
Jenessa N Johnston, Ioline D Henter, Carlos A Zarate
Harvard Review of Psychiatry
|
February 22, 2018
Glutamatergic Modulators in Depression
Ioline D Henter, Rafael Teixeira de Sousa, Carlos A Zarate
Expert Opinion on Pharmacotherapy
|
July 12, 2021
Key considerations in the pharmacological management of treatment-resistant depression
Mani Yavi, Ioline D Henter, Lawrence T Park, et al.
Dialogues in Clinical Neuroscience
|
November 3, 2009
The neurotrophic and neuroprotective effects of psychotropic agents
Joshua Hunsberger, Daniel R Austin, Ioline D Henter, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
September 13, 2013
Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?
Mark J Niciu, Ioline D Henter, Gerard Sanacora, et al.
JAMA Psychiatry
|
June 10, 2026
The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia: A Narrative Review
Gregory J Moore, Niranjan Bose, Ioline D Henter, et al.
Pharmacology, Biochemistry, and Behavior
|
October 6, 2011
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Rodrigo Machado-Vieira, Lobna Ibrahim, Ioline D Henter, et al.
Bioethics
|
May 16, 2017
The Ethics of Clinical Trials Research in Severe Mood Disorders
Allison C Nugent, Franklin G Miller, Ioline D Henter, et al.
CNS Spectrums
|
March 20, 2013
Defining anxious depression: a review of the literature
Dawn F Ionescu, Mark J Niciu, Ioline D Henter, et al.
Discover Mental Health
|
May 5, 2022
Ketamine treatment for depression: a review
Mani Yavi, Holim Lee, Ioline D Henter, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 71) with videos related to
Sort By:
Page
of 8
Pharmacology & Therapeutics
|
May 5, 2023
The antidepressant actions of ketamine and its enantiomers
Jenessa N Johnston, Ioline D Henter, Carlos A Zarate
Harvard Review of Psychiatry
|
February 22, 2018
Glutamatergic Modulators in Depression
Ioline D Henter, Rafael Teixeira de Sousa, Carlos A Zarate
Expert Opinion on Pharmacotherapy
|
July 12, 2021
Key considerations in the pharmacological management of treatment-resistant depression
Mani Yavi, Ioline D Henter, Lawrence T Park, et al.
Dialogues in Clinical Neuroscience
|
November 3, 2009
The neurotrophic and neuroprotective effects of psychotropic agents
Joshua Hunsberger, Daniel R Austin, Ioline D Henter, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
September 13, 2013
Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?
Mark J Niciu, Ioline D Henter, Gerard Sanacora, et al.
JAMA Psychiatry
|
June 10, 2026
The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia: A Narrative Review
Gregory J Moore, Niranjan Bose, Ioline D Henter, et al.
Pharmacology, Biochemistry, and Behavior
|
October 6, 2011
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Rodrigo Machado-Vieira, Lobna Ibrahim, Ioline D Henter, et al.
Bioethics
|
May 16, 2017
The Ethics of Clinical Trials Research in Severe Mood Disorders
Allison C Nugent, Franklin G Miller, Ioline D Henter, et al.
CNS Spectrums
|
March 20, 2013
Defining anxious depression: a review of the literature
Dawn F Ionescu, Mark J Niciu, Ioline D Henter, et al.
Discover Mental Health
|
May 5, 2022
Ketamine treatment for depression: a review
Mani Yavi, Holim Lee, Ioline D Henter, et al.
Page
of 8